Lookup NU author(s): Dr Andrew Gennery,
Professor Andrew Fisher
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2017 John Wiley & Sons Ltd. Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of erythrodermic cutaneous T-cell lymphoma (CTCL) and over 20 years for chronic and acute graft-versus-host disease (GvHD) and solid organ transplant rejection. ECP for CTCL and GvHD is available at specialised centres across the UK. The lack of prospective randomised trials in ECP led to the development of UK Consensus Statements for patient selection, treatment schedules, monitoring protocols and patient assessment criteria for ECP. The recent literature has been reviewed and considered when writing this update. Most notably, the national transition from the UVAR XTS® machine to the new CELLEX machine for ECP with dual access and a shorter treatment time has led to relevant changes in these schedules. This consensus statement updates the previous statement from 2007 on the treatment of CTCL and GvHD with ECP using evidence based medicine and best medical practise and includes guidelines for both children and adults.
Author(s): Alfred A, Taylor PC, Dignan F, El-Ghariani K, Griffin J, Gennery AR, Bonney D, Das-Gupta E, Lawson S, Malladi RK, Douglas KW, Maher T, Guest J, Hartlett L, Fisher AJ, Child F, Scarisbrick JJ
Publication type: Article
Publication status: Published
Journal: British Journal of Haematology
Print publication date: 01/04/2017
Online publication date: 21/02/2017
Acceptance date: 23/11/2016
ISSN (print): 0007-1048
ISSN (electronic): 1365-2141
Publisher: Blackwell Publishing Ltd
Altmetrics provided by Altmetric